StockNews.com Upgrades Blueprint Medicines (NASDAQ:BPMC) to Hold
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Friday. Other equities research analysts have also recently issued reports about the stock. Wedbush reissued an “outperform” rating and issued a $128.00 price objective on shares of Blueprint Medicines in […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Friday. Other equities research analysts have also recently issued reports about the stock. Wedbush reissued an “outperform” rating and issued a $128.00 price objective on shares of Blueprint Medicines in […]
